Enlivex Therapeutics (Nasdaq:ENLV) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ENLV Panoramica delle azioni

Enlivex Therapeutics Ltd., insieme alle sue controllate, opera in Israele come società di immunoterapia per la riprogrammazione dei macrofagi in fase clinica.

Informazioni sull'azienda

ENLV analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 17.6% all'anno per i prossimi 3 anni

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Non ha una capitalizzazione di mercato significativa ( $26M )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

+ 1 più rischio

Enlivex Therapeutics Ltd. Concorrenti

LianBio

OTCPK:LIAN.Y

US$31.9m

AgeX Therapeutics

NYSEAM:AGE

US$31.5m

Lumos Pharma

NasdaqGM:LUMO

US$32.6m

Estrella Immunopharma

NasdaqCM:ESLA

US$30.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Enlivex Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.52
Massimo di 52 settimane	US$4.59
Minimo di 52 settimane	US$1.15
Beta	1.04
1Variazione di 1 mese	-1.94%
Variazione a 3 mesi	12.18%
Variazione di 1 anno	10.95%
3Variazione a 3 anni	-82.01%
Variazione a 5 anni	-80.61%
Variazione dall'IPO	-85.24%

Notizie e aggiornamenti recenti

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13

Recent updates

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Apr 04

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Dec 13

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Jul 25

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Apr 05

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Nov 16

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 30

Enlivex to gets US patent covering use of cell therapy Allocetra

Sep 06

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Aug 29

Envilex Therapeutics reports Q2 results

Aug 22

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Jul 08

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Jul 06

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Mar 23

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Nov 25

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Aug 12

Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy

Jun 15

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Jan 11

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

Nov 19

Rendimenti per gli azionisti

	ENLV	US Biotechs	US Mercato
7D	4.1%	2.8%	1.1%
1Y	10.9%	26.9%	36.0%

Ritorno vs Industria: ENLV ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 21.6 % nell'ultimo anno.

Rendimento vs Mercato: ENLV ha avuto una performance inferiore al mercato US che ha registrato un rendimento 24.7 % nell'ultimo anno.

Volatilità dei prezzi

Is ENLV's price volatile compared to industry and market?
ENLV volatility
ENLV Average Weekly Movement	9.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.7%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: ENLV non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di ENLV è diminuita da 16% a 8% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	n/a	Oren Hershkovitz	www.enlivex.com

Enlivex Therapeutics Ltd., insieme alle sue controllate, opera in Israele come società di immunoterapia per la riprogrammazione dei macrofagi in fase clinica. La sua pipeline di prodotti è costituita da Allocetra, che è in fase II di sperimentazione clinica per il trattamento della disfunzione d'organo causata dalla sepsi. L'azienda sviluppa inoltre Allocetra per il trattamento dell'osteoartrite moderata del ginocchio e dell'osteoartrite del ginocchio in fase terminale, in fase di sperimentazione clinica I/II.

Enlivex Therapeutics Ltd. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Enlivex Therapeutics con la sua capitalizzazione di mercato?
ENLV statistiche fondamentali
Capitalizzazione di mercato	US$34.89m
Guadagni(TTM)	-US$22.29m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-1.5x

Rapporto P/E

ENLV è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ENLV Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$22.29m
Guadagni	-US$22.29m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.04
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato ENLV nel lungo periodo?

Vedi performance storica e confronto

ENLV Panoramica delle azioni

Premi

Analisi del rischio

Enlivex Therapeutics Ltd. Concorrenti

OTCPK:LIAN.Y

US$31.9m

NYSEAM:AGE

US$31.5m

NasdaqGM:LUMO

US$32.6m

NasdaqCM:ESLA

US$30.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Recent updates

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased by 20% to US$12.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Intends to Reduce its Workforce by Approximately 50%

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

New major risk - Financial position

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$15.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex to gets US patent covering use of cell therapy Allocetra

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Envilex Therapeutics reports Q2 results

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Price target increased to US$33.00

Insufficient new directors

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece